122 related articles for article (PubMed ID: 32534194)
1. Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H
Nirogi R; Bhyrapuneni G; Muddana NR; Manoharan A; Shinde AK; Mohammed AR; Padala NP; Ajjala DR; Subramanian R; Palacharla VRC
Eur J Pharm Sci; 2020 Sep; 152():105425. PubMed ID: 32534194
[TBL] [Abstract][Full Text] [Related]
2. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Nirogi R; Benade V; Daripelli S; Subramanian R; Kamuju V; Bhyrapuneni G; Muddana NR; Mekala VR; Petlu S; Jayarajan P; Badange R; Shinde A; Jasti V
Psychopharmacology (Berl); 2021 Jun; 238(6):1495-1511. PubMed ID: 33550481
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
[TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment.
Nirogi R; Ajjala DR; Prakash Padala NS; Kalaikadhiban I; Rayapati LP; Chunduru P; Shinde A
Bioanalysis; 2020 Apr; 12(8):533-544. PubMed ID: 32351118
[No Abstract] [Full Text] [Related]
5. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H
Nirogi R; Shinde A; Mohammed AR; Badange RK; Reballi V; Bandyala TR; Saraf SK; Bojja K; Manchineella S; Achanta PK; Kandukuri KK; Subramanian R; Benade V; Palacharla RC; Jayarajan P; Pandey S; Jasti V
J Med Chem; 2019 Feb; 62(3):1203-1217. PubMed ID: 30629436
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract][Full Text] [Related]
7. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders.
Nirogi R; Grandhi VR; Medapati RB; Ganuga N; Benade V; Gandipudi S; Manoharan A; Abraham R; Jayarajan P; Bhyrapuneni G; Shinde A; Badange RK; Subramanian R; Petlu S; Jasti V
J Psychopharmacol; 2021 Jun; 35(6):713-729. PubMed ID: 33546570
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
10. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
11. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
Lam JL; Benet LZ
Drug Metab Dispos; 2004 Nov; 32(11):1311-6. PubMed ID: 15483198
[TBL] [Abstract][Full Text] [Related]
12. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.
Hamill TG; Sato N; Jitsuoka M; Tokita S; Sanabria S; Eng W; Ryan C; Krause S; Takenaga N; Patel S; Zeng Z; Williams D; Sur C; Hargreaves R; Burns HD
Synapse; 2009 Dec; 63(12):1122-32. PubMed ID: 19670309
[TBL] [Abstract][Full Text] [Related]
13. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
[TBL] [Abstract][Full Text] [Related]
14. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
[TBL] [Abstract][Full Text] [Related]
15. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.
Grillo MP; Erve JCL; Dick R; Driscoll JP; Haste N; Markova S; Brun P; Carlson TJ; Evanchik M
Xenobiotica; 2019 Jun; 49(6):718-733. PubMed ID: 30044681
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H
Terasaka S; Hachiuma K; Mano Y; Onishi K; Kitajima I; Nishino I; Endo H
Xenobiotica; 2021 Jul; 51(7):786-795. PubMed ID: 33910470
[TBL] [Abstract][Full Text] [Related]
18. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
[TBL] [Abstract][Full Text] [Related]
20. In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.
Carlile DJ; Stevens AJ; Ashforth EI; Waghela D; Houston JB
Drug Metab Dispos; 1998 Mar; 26(3):216-21. PubMed ID: 9492383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
